Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Damora Therapeutics, Inc.DMRA · Entity 4602 | SVP, Finance | May 01, 2026 | May 08, 2026 |
| IO Biotech, Inc.IOBT · Entity 8764 | Chief Accounting Officer | April 02, 2025 | April 04, 2025 |
| Passage BIO, Inc.PASG · Entity 7829 | Controller | May 30, 2021 | June 09, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Damora Therapeutics, Inc.
Report date May 01, 2026 · Filed May 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.00 · Expires 2035-12-15 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-05-01 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: This option represents a right to purchase shares of common stock of the Issuer. This option will vest as to 25% on December 15, 2026 and in equal monthly installments thereafter through December 15, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option represents a right to purchase shares of common stock of the Issuer. This option will vest as to 25% on December 15, 2026 and in equal monthly installments thereafter through December 15, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
IO Biotech, Inc.
Report date April 02, 2025 · Filed April 04, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.07 · Expires 2035-04-02 | Direct | 65,000 |
Reported balance
After 2025-04-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-04-02 · Grant · Acquired 65,000 · Balance 65,000 F1: One-fourth of these options vest on April 2, 2026, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 25% acceleration upon termination of service by the issuer without cause and 100% acceleration upon termination of service by the Issuer without cause if such termination occurs within 24 months of a change of control. |
Filing footnotes · ownership attribution and instrument terms
F1: One-fourth of these options vest on April 2, 2026, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 25% acceleration upon termination of service by the issuer without cause and 100% acceleration upon termination of service by the Issuer without cause if such termination occurs within 24 months of a change of control.
Passage BIO, Inc.
Report date May 30, 2021 · Filed June 09, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.63 · Expires 2030-07-14 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-05-30 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The stock option vested as to 25% of the total shares on July 15, 2021, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.85 · Expires 2031-02-15 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-05-30 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: The stock option vests as to 25% of the total shares on February 16, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vested as to 25% of the total shares on July 15, 2021, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F2: The stock option vests as to 25% of the total shares on February 16, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 02, 2025 Filed Apr 4, 2025 20:12 UTC | IO Biotech, Inc. IOBT · Entity 8764 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0000905148-25-001093 · form4.xml · derivative · entry 1 Burkavage Brian · CIK 0001865633 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2035-04-02 F1 · derivative.exercise_date: One-fourth of these options vest on April 2, 2026, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 25% acceleration upon termination of service by the issuer without cause and 100% acceleration upon termination of service by the Issuer without cause if such termination occurs within 24 months of a change of control. Read SEC document |
| March 15, 2024 Filed Mar 18, 2024 20:22 UTC | IO Biotech, Inc. IOBT · Entity 8764 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0000905148-24-000967 · form4.xml · derivative · entry 1 Burkavage Brian · CIK 0001865633 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-03-15 F1 · derivative.exercise_date: One-fourth of these options vest on March 15, 2025, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 25% acceleration upon termination of service by the issuer without cause and 100% acceleration upon termination of service by the Issuer without cause if such termination occurs within 24 months of a change of control. Read SEC document |
| November 22, 2023 Filed Nov 24, 2023 22:37 UTC | IO Biotech, Inc. IOBT · Entity 8764 | PurchaseCommon Stock | 5,000 | $1.04 | $5,175.00 |
DisclosureSEC source: 0000905148-23-001527 · form4.xml · nonDerivative · entry 2 Burkavage Brian · CIK 0001865633 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,500 F1 · price: The transaction was executed in multiple trades in prices ranging from $1.03 to $1.04, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote. Read SEC document |
| November 21, 2023 Filed Nov 24, 2023 22:37 UTC | IO Biotech, Inc. IOBT · Entity 8764 | PurchaseCommon Stock | 5,000 | $0.99 | $4,950.00 |
DisclosureSEC source: 0000905148-23-001527 · form4.xml · nonDerivative · entry 1 Burkavage Brian · CIK 0001865633 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,500 Read SEC document |
| March 20, 2023 Filed Mar 22, 2023 20:21 UTC | IO Biotech, Inc. IOBT · Entity 8764 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.98 | $0.00 |
DisclosureSEC source: 0001140361-23-013072 · form4.xml · derivative · entry 1 Burkavage Brian · CIK 0001865633 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-03-20 F1 · derivative.exercise_date: One-fourth of these options vest on March 20, 2024, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 50% acceleration upon a change of control and subject to 100% acceleration upon termination of service by the Issuer without cause within 24 months of a change of control. Read SEC document |
| May 31, 2022 Filed Jun 2, 2022 22:25 UTC | IO Biotech, Inc. IOBT · Entity 8764 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $4.83 | $0.00 |
DisclosureSEC source: 0001567619-22-012194 · doc1.xml · derivative · entry 1 Burkavage Brian · CIK 0001865633 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-05-31 F1 · derivative.exercise_date: One-fourth of these options vest on 5/31/2023, and 1/48th of these options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 50% acceleration upon a change of control and subject to 100% acceleration upon termination of service by the Issuer without cause within 24 months of a change of control. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.